PROVETOP
Request a Quote

Human HLA-A*02:01&B2M&CG1 (FLLPTGAEA) Monomer Protein

Catalog No: HLAA0201-HP013

Species
Human
Expression System
E. coli
Tag
His, Avi

Product overview

Recombinant Human HLA-A*02:01&B2M&CG1 (FLLPTGAEA) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and FLLPTGAEA peptide (accession: A0A140T913(HLA-A*02:01) & P61769(B2M) &FLLPTGAEA).

Product Details

Molecular Aliases
CG1 (FLLPTGAEA)
Protein Length
Gly25-Thr305
Expression System
E. coli
Theoretical Molecular Weight
The protein has a predicted MW of 35.6 kDa (HLA-A*02:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Supplied as 0.22 μm filtered solution in 20mM Tris, 200mM NaCl (pH 8.0).
State
Liquid
Storage Conditions
Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Data Display

Bis-Tris PAGE
HLAA0201-HP013 Bis-Tris-PAGE-white result

Human HLA-A*02:01&B2M&CG1 (FLLPTGAEA) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC
HLAA0201-HP013 SEC-HPLC result

The purity of Human HLA-A*02:01&B2M&CG1 (FLLPTGAEA) Monomer is greater than 95% as determined by SEC-HPLC.

Background

Cathepsin G (CG) is a myeloid azurophil granule protease that is highly expressed by acute myeloid leukemia (AML) blasts and leukemia stem cells. CG1 (FLLPTGAEA) is a human leukocyte antigen-A2-restricted nonameric peptide derived from CG that can act as an immunogenic target in AML.

References

  1. [1] Khan M, Carmona S, Sukhumalchandra P, Roszik J, Philips A, Perakis AA, Kerros C, Zhang M, Qiao N, John LSS, Zope M, Goldberg J, Qazilbash M, Jakher H, Clise-Dwyer K, Qiu Y, Mittendorf EA, Molldrem JJ, Kornblau SM, Alatrash G. Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target. Front Immunol. 2018 Jan 25;8:1975. doi: 10.3389/fimmu.2017.01975. PMID: 29422892; PMCID: PMC5790053.
  2. [2] Shi C, Tian Z, Yan J, Zhang M, Sukhumalchandra P, Chang E, Yang G, You J, Cui M, Shi Q, Kerros C, Philips A, Qiao N, Torikai H, Patchametla S, Sergeeva A, St John L, He H, Wiederschain D, Lee BH, Paulus GLC, Zha D, Molldrem J, Alatrash G. Immunotherapy targeting a leader sequence cathepsin G-derived peptide. Leukemia. 2025 Apr;39(4):888-898. doi: 10.1038/s41375-025-02520-x. Epub 2025 Feb 12. PMID: 39939820; PMCID: PMC11976275.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support